Quantcast

Latest Amides Stories

2014-07-28 23:01:24

Advanced Recovery, Absorption & Immune System Support* New York, NY (PRWEB) July 28, 2014 Glutamine is the most abundant single amino acid in the body and it’s considered to be conditionally essential during times when the body undergoes large amounts of stress and is an advanced recovery & Immune System Support. Having a heavy work out regimen, burns all the glutamine your body produces, supplementing with additional glutamine may be advantageous. Glutamine supplementation may...

2014-07-27 23:02:21

Reports of Xarelto Bleeding Mounts As Doctors Are Prescribing Xarelto Over Pradaxa and Seeing a Rise In Adverse Events While Xarelto Lawsuits Begin to be Filed Reports Wright & Schulte LLC Columbus, OH (PRWEB) July 27, 2014 The Institute of Safe Medication Practices (ISMP) Found that the number of serious adverse events such as Xarelto bleeding side-effects reported after the use of the Xarelto blood thinner has now out numbered the complaints filed for its competitor Pradaxa, notes...

2014-07-25 04:21:37

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR(®) (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an...

2014-07-23 16:26:55

British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran etexilate mesylate). We are concerned that this publication may alarm patients and prompt them to stop taking PRADAXA, thereby increasing their risk of stroke. To be clear, many of the allegations made...

2014-07-14 08:26:37

SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company. Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf...

2014-07-09 23:04:27

Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, notes that Xarelto® is surpassing Pradaxa® in the number of reported adverse events, according to the Institute for Safe Medication Practices’ most recent Quarter Watch Report. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have suffered serious bleeding events after using Xarelto®. St. Louis, MO (PRWEB) July 09, 2014 According to...

2014-07-07 08:22:14

-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase III DECISION trial TORONTO, July 7, 2014 /CNW/ - Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally...

2014-06-30 08:30:17

SAN ANTONIO, June 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California. Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202. Summary: -- G-202 Data in Hepatocellular (HCC) Patients...

2014-06-26 08:28:27

Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to idarucizumab*, an investigational fully humanized antibody fragment, or Fab, being studied as a specific antidote for Pradaxa (dabigatran etexilate mesylate). "Boehringer Ingelheim is pleased that the...

2014-06-24 12:28:44

RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access program (EAP) for its investigational compound nintedanib, for people diagnosed with idiopathic pulmonary fibrosis (IPF) and who meet certain eligibility criteria. Nintedanib is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA). The safety and efficacy of...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related